Rodger E Tiedemann
Affiliation: Mayo Clinic
- Identification of a potent natural triterpenoid inhibitor of proteosome chymotrypsin-like activity and NF-kappaB with antimyeloma activity in vitro and in vivoRodger E Tiedemann
Division of Hematology and Oncology, Comprehensive Cancer Center, Mayo Clinic, Scottsdale, AZ 85259, USA
Blood 113:4027-37. 2009....
- Kinome-wide RNAi studies in human multiple myeloma identify vulnerable kinase targets, including a lymphoid-restricted kinase, GRK6Rodger E Tiedemann
Division of Hematology Oncology, Mayo Clinic Arizona, 13400 Shea Blvd, Scottsdale, AZ 85259, USA
Blood 115:1594-604. 2010..As mice that lack GRK6 are healthy, inhibition of GRK6 represents a uniquely targeted novel therapeutic strategy in human multiple myeloma...
- Identification of kinetin riboside as a repressor of CCND1 and CCND2 with preclinical antimyeloma activityRodger E Tiedemann
Mayo Clinic, Comprehensive Cancer Center, Division of Hematology and Oncology, Scottsdale, Arizona, USA
J Clin Invest 118:1750-64. 2008..These data support targeted repression of cyclin D genes as a therapeutic strategy for human malignancies...